In a promising development in fight against mosquito-borne dengue infections, a dengue vaccine, Qdenga, also called TAK-003, developed by a Japanese firm, which will also be manufactured by a Hyderabad-based pharma company, has shown lasting effects and more than 50 percent efficacy. It is a live-attenuated vaccine, containing weakened versions of the four serotypes of the DENV virus.